Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Comparison of FSH flare with and without pretreatment with oral contraceptive pills in poor responders undergoing in vitro fertilization  Martin D. Keltz,
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Variation in circulating antimüllerian hormone precursor during the periovulatory and acute postovulatory phases of the human ovarian cycle  Michael W.
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Male contraception Fertility and Sterility
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
The normal variabilities of the menstrual cycle
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression 
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone  M. Yusoff Dawood, M.D.,
Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D
Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women  Ioannis E. Messinis, M.D., Ph.D.,
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency  Carrie.
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.
Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.
Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D
Robert F. Casper, M.D.  Fertility and Sterility 
Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study  Frederic Mitri,
Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration 
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone 
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Variations in l-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with.
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis  Dimitra Kyrou,
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells  Toshiaki Taketani, M.D., Yoshiaki.
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer  Mohamed.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Fertility and Sterility
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles 
Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development 
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle- stimulating hormone (FSH) in normoandrogenic ovulatory women.
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Presentation transcript:

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh T. Nguyen, M.D., Anthony P. Cheung, M.B., B.S., M.P.H., Peter C.K. Leung, Ph.D.  Fertility and Sterility  Volume 92, Issue 2, Pages 499-507 (August 2009) DOI: 10.1016/j.fertnstert.2008.06.039 Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Estradiol, FSH, and LH concentrations in the flare and luteal protocols during coasting. (A and B) Estradiol. (A) Flare protocol: GnRH agonists (GnRH-a) stop group, n = 9 cycles. GnRH-a were stopped on day -1. GnRH-a continue group, n = 7 cycles. Agonists were continued throughout the coast until the day of hCG or cycle cancellation (day 0). (B) Luteal protocol: GnRH-a stop group, n = 8 cycles. The agonists were stopped on day -1. GnRH-a continue group, n = 35 cycles. Agonists were continued throughout the coast until day 0. In this and subsequent figures, data are shown for the last 4 days of coasting (day -3 to day 0) and are displayed as mean ∀ SEM. Mean values were statistically compared on day -1 and day 0. aP<.05. (C and D) FSH. (C) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (D) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. (E and F) LH. (E) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (F) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. Fertility and Sterility 2009 92, 499-507DOI: (10.1016/j.fertnstert.2008.06.039) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Progesterone, androstenedione (A), and anti-Müllerian hormone (AMH) concentrations in the flare and luteal protocols during coasting. (A and B) Progesterone. (A) Flare protocol: GnRH agonists (GnRH-a) stop group, n = 8 cycles. GnRH-a were stopped on day -1. GnRH-a continue group, n = 4 cycles. The agonists were continued throughout the coast until the day of hCG administration or cycle cancellation (day 0). (B) Luteal protocol: GnRH-a stop group, n = 7 cycles. The agonists were stopped on day -1. GnRH-a continue group, n = 9 cycles, Agonists were continued throughout the coast until day 0. In this and subsequent figures, data are shown for the last 4 days of coasting (day -3 to day 0) and are displayed as mean ∀ SEM. Mean values were statistically compared on day -1 and day 0. aP<.05. (C and D) Androstenedione. (C) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (D) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. (E and F) AMH. (E) Flare protocol: GnRH-a stop group, n = 9 cycles. GnRH-a continue group, n = 4 cycles. (F) Luteal protocol: GnRH-a stop group, n = 7 cycles. GnRH-a continue group, n = 10 cycles. Fertility and Sterility 2009 92, 499-507DOI: (10.1016/j.fertnstert.2008.06.039) Copyright © 2009 American Society for Reproductive Medicine Terms and Conditions